Long-term follow-up after adjuvant chemotherapy in completely resected early stage ovarian carcinoma

European Journal of Obstetrics and Gynecology and Reproductive Biology

Volumn 72, Issue 2, 1997, Pages 181-190

  Raymond, Eric ^a   Drolet, Yvan ^a   Marpeau, Loïc ^a   Louvet, Christophe ^a   Cady, Jean ^a   Tessier, Claude ^a   Faivre, Sandrine ^a   Quellet, Pierre ^a   Lavoie, André ^a   Rioux, Ernest ^a   De Gramont, Aimery ^a   Krulik, Marcel ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

Alkylating agent; Cisplatin; Melphalan; Prognosis of relapse; Prognostic factor

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANISETRON; MELPHALAN; METOCLOPRAMIDE; ONDANSETRON;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ALOPECIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; LAPAROTOMY; LEUKOPENIA; LONG TERM CARE; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PERIPHERAL NEUROPATHY; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; SALPINGOOOPHORECTOMY; THROMBOCYTOPENIA; VOMITING;

EID: 0031127994     PISSN: 03012115     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-2115(96)02672-3     Document Type: Article

References (40)

1. [1] Young RC. Management of early stage ovarian cancer. In: Cancer of the Ovary. New York: Raven Press, 1993.
2. [2] Rezvani A, Lê MG. Evolution de la mortalité par cancer de l'ovaire en France entre 1968 et 1991. Bull Cancer 1994; 81: 1091-1095.
3. [3] Tate Thigpen J, Lambuth BW, Vance RB. Management of stage I and II ovarian carcinoma. Semin Oncol 1991; 18: 596-602.
4. [4] Young RC, Decker DG, Wharton JT, Piver MS, Sindelar WF, Edwards BK, Smith JP. Staging laparotomy in early ovarian cancer. JAMA 1983; 250: 3072-3076.
5. [5] Lentz SS, Cha SS, Wieand HS, Podratz KC. Stage I ovarian epithelial carcinoma: survival analysis following definitive treatment. Gynecol Oncol 1971; 43: 198-202.
6. [6] Björkholm E, Pettersson F, Einhorn P, Krebs I, Nilsson B, Tjernberg B. Long-term follow-up and prognostic factors in ovarian carcinoma. The rediumhemmet series 1958 to 1973. Acta Radiol Oncol 1982; 21: 413-419.
7. [7] Warlton LA, Yadusky A, Rubinstein L, Roth LM, Young RC. Stage II carcinoma of the ovary: an analysis of survival after comprehensive surgical staging and adjuvant therapy. Gynecol Oncol 1992; 44: 55-60.
8. [8] Young RC, Walton LA, Ellenberg SS, Homesley HD, Wilbanks GD, Decker DG, Miller A, Park R, Major F. Adjuvant therapy in stage I and stage II epithelial ovarian cancer. Resuts of two prospective randomized trials. N Engl J Med 1990; 322: 1021-1027.
9. [9] Einhorn N, Nilsson B, Sjövall K. Factors influencing survival in carcinoma of the ovary. Study from a well-defined Swedish population. Cancer 1985; 55: 2019-2025.
10. [10] Webb MJ, Decker DG, Mussey E, Williams TJ. Factors influencing survival in stage I ovarian cancer. Am J Obstet Gynecol 1973; 116: 222-228.
11. [11] Omura G, Blessing JA, Ehrlich CE, Miller A, Yordan E, Creasman WT, Homesley HD. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma, a gynecologic oncology group study. Cancer 1986; 57: 1725-1730.
12. [12] Conte PF, Bruzzone M, Chiara S, Sertoli MR, Daga MG, Rubagotti A, Conio A, Ruvolo M, Rosso R, Santi L, Carnino F, Cottini M, Mosseti C, Guercio E, et al. A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer. J Clin Oncol 1986; 4: 965-971.
13. [13] Omura GA, Bundy BN, Berek JS, Curry S, Delgado G, Mortel R. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a gynecologic oncology group study. J Clin Oncol 1989; 7: 457-465.
14. [14] De Gramont A, Demuynck B, Varette C, Louvet C, Pigne A, Marpeau L, Lagadec B, Cady J, et al. Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer. Eur J Cancer 1992; 28: 53-58.
15. [15] Rubin SC, Wong GY, Curtin JP, Barakat RR, Hakes TB, Hoskins WJ. Platinum-based chemotherapy of high-risk stage I epithelial ovarian cancer following comprehensive surgical staging. Obstet Gynecol 1993; 82: 143-146.
16. [16] Piver MS, Malfetano J, Baker TR, Lele SB, Marchetti DL. Adjuvant cisplatin-based chemotherapy for stage I ovarian adenocarcinoma: a preliminary report. Gynecol Oncol 1989; 35: 69-72.
17. [17] Piver MS, Malfetano J, Baker TR, Hempling RE. Five year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol 1992; 46: 357-360.
18. [18] Dottino PR, Plaxe SC, Cohen CJ. A phase II trial of adjuvant cisplatin and doxorubicin in stage I epithelial ovarian cancer. Gynecol Oncol 1991; 43: 203-205.
19. [19] Chiara S, Mammoliti S, Oliva C, Merlini L, Bruzzone M, Sertoli MR, Parodi GC, Ragni N, Foglia G, Odicino F. Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7 year experience. Eur J Cancer 1991; 27: 1211-1215.
20. [20] Bolis G, Colombo N, Pecorelli S, Torri V, Marsoni S, Bonazzi C, Chiari S, Favalli G, Mangili G, Presti M, Zanaboni F, Mangioni C. Adjuvant treatment for early epithelial ovarian cancer: results of two randomized clinical trials comparing cisplatin to no further treatment or chromic phosphate (32P). Ann Oncol 1995; 6: 887-893.
21. [21] Meier W, Stieber P, Eiermann W, Schneider A, Fateh-Moghadam A, Hepp H. Serum levels of CA 125 and histological findings at second-look laparotomy in ovarian carcinoma. Gynecol Oncol 1989; 35: 44-46.
22. [22] Zurawski VR, Broderick SF, Pickens P, Knapp RC, Bast RC. Serum CA 125 levels in a group of nonhospitalized women: relevance for the early detection of ovarian cancer. Obstet Gynecol 1987; 69: 606-611.
23. [23] Nagele F, Petru E, Meld M, Kainz C, Graf AH, Sevelda P. Preoperative CA 125: An independent prognostic factor in patients with stage I epithelial ovarian cancer. Obstet Gynecol 1995; 86: 259-264.
24. [24] Trimbos JB, Schueler JA, Van der Burg M, Hermans J, Van Lent M, Heintz APM, Fleuren GJ. Cancer 1991; 67: 597-602.
25. [25] McGowan L, Parent Lesher L, Norris HJ, Barnett M. Mistaging of ovarian cancer. Obstet Gynecol 1985; 65: 568-572.
26. [26] Schneider J, Centeno MM, Montoya F, Rodriguez-Escudero FJ. Negative second-look laparotomy does not preclude recurrence in stage I ovarian carcinoma of any histological variety. Eur J Gynaecol Oncol 1993; 14: 36-39.
27. [27] Piver MS, Barlow JJ, Lele SB. Incidence of subclinical metastasis in stage I and II ovarian carcinoma. Obstet Gynecol 1978; 52: 100-104.
28. [28] Walton L, Ellenberg SS, Major F, Miller A, Park R, Young RC. Results of second-look laparotomy in patients with early-stage ovarian carcinoma. Obstet Gynecol 1987; 70: 770-773.
29. [29] Knapp RC, Friedman EA. Aortic lymph node metastases in early ovarian cancer. Obstet Gynecol 1974; 119: 1013-1017.
30. [30] Piver MS, Lele SB, Patsner B, Krishnamsetty R, Emrich LJ. Stage II invasive adenocarcinoma of the ovary: results of treatment by whole abdominal radiation plus pelvic boost versus pelvic radiation plus oral melphalan chemotherapy. Gynecol Oncol 1986; 23: 168-175.
31. [31] Sell A, Bertelsen K., Andersen JE, Stroyer I, Panduro J. Randomized study of whole-abdomen irradiation versus pelvic irradiation plus cyclophosphamide in treatment of early ovarian cancer. Gynecol Oncol 1990; 37: 367-373.
32. [32] Pezner RD, Stevens KR, Tong D, Allen CV. Limited epithelial carcinoma of the ovary treated with curative intent by the intraperitoneal installation of radiocolloids. Cancer 1978; 42: 2563-2571.
33. [33] Spencer TR, Marks RD, Fenn JO, Jenrette JM, Lutz MH. Intraperitoneal P-32 after negative second-look laparotomy in ovarian carcinoma. Cancer 1989; 63: 2434-2437.
34. [34] Hreshchyshyn MM, Park RC, Blessing JA, Norris HJ, Levy D, Lagasse LD, Creasman WT. The role of adjuvant therapy in early stage I ovarian cancer. Am J Obstet Gynecol 1980; 138: 139-145.
35. [35] Gallion HH, Van Nagell JR, Donaldson ES, Higgins RV, Powell DE, Kryscio RJ. Adjuvant oral alkylating chemotherapy in patients with stage I epithelial ovarian cancer. Cancer 1989; 63: 1070-1073.
36. [36] Davy M, Stenwig AE, Kjorstad KE, Berle E. Early stage ovarian cancer. The effect of adjuvant treatment with single alkylating agent. Acta Obstet Gynecol Scand 1985; 64: 531-532.
37. [37] Monga M, Carmichael A, Shelley WE, Kirk ME, Krepart GV, Jeffrey JF, Pater JL. Surgery without adjuvant chemotherapy for early epithelial ovarian carcinoma after comprehensive surgical staging. Gynecol Oncol 1991; 43: 195-197.
38. [38] Smith JP, Rutledge FN, Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl Cancer Inst Monogr 1975; 42: 149-153.
39. [39] Dembo AJ, Bush RS, Beale FA, Bean HA, Pringle JF, Sturgeon JFG. The princess Margaret hospital study of ovarian cancer: stage I and II and asymptomatic III presentations. Cancer Treat Rep 1979; 63: 249-254.
40. [40] Klaassen D, Shelley W, Starreveld A, Kirk M, Boyes D, Gerulath A, Levitt M, Fraser R, Carmichael J, Methot Y, Willan A. Early stage ovarian cancer: a randomized clinical trial comparing whole abdominal radiotherapy, melphalan, and intraperitoneal chromic phosphate: a national cancer institute of Canada clinical trials group report. J Clin Oncol 1988; 6: 1254-1263.